E. T. Wang, R. Sandberg, S. Luo, I. Khrebtukova, and L. Zhang, Alternative isoform regulation in human tissue transcriptomes, Nature, vol.456, pp.470-476, 2008.

A. Srebrow and A. R. Kornblihtt, The connection between splicing and cancer, J Cell Sci, vol.119, pp.2635-2641, 2006.

J. P. Venables, Aberrant and alternative splicing in cancer Cancer Res, vol.64, pp.7647-7654, 2004.

B. M. Brinkman, Splice variants as cancer biomarkers, Clin Biochem, vol.37, pp.584-94, 2004.

L. Xi, A. Feber, V. Gupta, M. Wu, and A. D. Bergemann, Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer, Nucleic Acids Res, vol.36, pp.6535-6547, 2008.

C. M. Misquitta-ali, E. Cheng, D. O'hanlon, N. Liu, and C. J. Mcglade, Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer, Mol Cell Biol, vol.31, pp.138-150, 2011.

C. Salon, B. Eymin, O. Micheau, L. Chaperot, and J. Plumas, E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptormediated apoptosis through specific downregulation of c-FLIP(short), Cell Death Differ, vol.13, pp.260-272, 2006.

G. Merdzhanova, V. Edmond, D. Seranno, S. Van-den-broeck, A. Corcos et al., E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35, Cell Death Differ, vol.15, pp.1815-1823, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00360967

G. Merdzhanova, S. Gout, M. Keramidas, V. Edmond, and J. L. Coll, The transcription factor E2F1 and the SR protein SC35 control the ratio of proangiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo, Oncogene, vol.29, pp.5392-5403, 2010.

V. Edmond, E. Moysan, S. Khochbin, P. Matthias, and C. Brambilla, Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin, EMBO J, vol.30, pp.510-523, 2011.

A. M. Groeger, V. Esposito, D. Luca, A. Cassandro, R. Tonini et al., Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers, Histopathology, vol.44, pp.54-63, 2004.

T. Hirata, T. Fukuse, H. Naiki, S. Hitomi, and H. Wada, Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor, Cancer Res, vol.58, pp.1108-1110, 1998.

S. C. Evans, M. Viswanathan, J. D. Grier, M. Narayana, and A. K. El-naggar, An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2, Oncogene, vol.20, pp.4041-4049, 2001.

R. Pio and L. M. Montuenga, Alternative splicing in lung cancer, J Thorac Oncol, vol.4, pp.674-678, 2009.

E. Kim, A. Goren, and G. Ast, Insights into the connection between cancer and alternative splicing, Trends Genet, vol.24, pp.7-10, 2008.

M. L. Hastings and A. R. Krainer, Pre-mRNA splicing in the new millennium, Curr Opin Cell Biol, vol.13, pp.302-309, 2001.

J. C. Long and J. F. Caceres, The SR protein family of splicing factors: master regulators of gene expression, Biochem J, vol.417, pp.15-27, 2009.

A. M. Zahler, W. S. Lane, J. A. Stolk, and M. B. Roth, SR proteins: a conserved family of pre-mRNA splicing factors, Genes Dev, vol.6, pp.837-847, 1992.

J. Y. Wu and T. Maniatis, Specific interactions between proteins implicated in splice site selection and regulated alternative splicing, Cell, vol.75, pp.1061-1070, 1993.

S. H. Xiao and J. L. Manley, Phosphorylation-dephosphorylation differentially affects activities of splicing factor ASF/SF2, EMBO J, vol.17, pp.6359-6367, 1998.

J. F. Gui, W. S. Lane, and X. D. Fu, A serine kinase regulates intracellular localization of splicing factors in the cell cycle, Nature, vol.369, pp.678-82, 1994.

K. Colwill, T. Pawson, B. Andrews, J. Prasad, and J. L. Manley, The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution, EMBO J, vol.15, pp.265-275, 1996.

T. K. Ko, E. Kelly, and J. Pines, CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles, J Cell Sci, vol.114, pp.2591-2603, 2001.

M. Blaustein, F. Pelisch, T. Tanos, M. J. Munoz, and D. Wengier, Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT, Nat Struct Mol Biol, vol.12, pp.1037-1044, 2005.

R. Karni, E. De-stanchina, S. W. Lowe, R. Sinha, and D. Mu, The gene encoding the splicing factor SF2/ASF is a proto-oncogene, Nat Struct Mol Biol, vol.14, pp.185-193, 2007.

T. Ezponda, M. J. Pajares, J. Agorreta, J. I. Echeveste, and J. M. Lopez-picazo, The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression, Clin Cancer Res, vol.16, pp.4113-4125, 2010.

W. D. Travis, E. Brambilla, H. K. Muller-hemerlink, and C. C. Harris, World Health Organization classification of tumours. Pathology and Genetics of tumours of the lung, pleura, thymus and heart, 2004.

J. F. Caceres, G. R. Screaton, and A. R. Krainer, A specific subset of SR proteins shuttles continuously between the nucleus and the cytoplasm, Genes Dev, vol.12, pp.55-66, 1998.

Y. Shintani, A. Okimura, K. Sato, T. Nakagiri, and Y. Kadota, Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer, Ann Thorac Surg, vol.92, pp.1794-1804, 2011.

O. Anczukow, A. Z. Rosenberg, M. Akerman, S. Das, and L. Zhan, The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation, Nat Struct Mol Biol, vol.19, pp.220-228, 2012.

C. Ghigna, S. Giordano, H. Shen, F. Benvenuto, and F. Castiglioni, Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene, Mol Cell, vol.20, pp.881-890, 2005.

C. Schwerk and K. Schulze-osthoff, Regulation of apoptosis by alternative pre-mRNA splicing, Mol Cell, vol.19, pp.1-13, 2005.

A. Piekielko-witkowska, H. Wiszomirska, A. Wojcicka, P. Poplawski, and J. Boguslawska, Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors, PLoS One, vol.5, p.13690, 2010.

E. Stickeler, F. Kittrell, D. Medina, and S. M. Berget, Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis, Oncogene, vol.18, pp.3574-3582, 1999.

D. C. Fischer, K. Noack, I. B. Runnebaum, D. O. Watermann, and D. G. Kieback, Expression of splicing factors in human ovarian cancer, Oncol Rep, vol.11, pp.1085-1090, 2004.

S. Mole, M. Mcfarlane, T. Chuen-im, S. G. Milligan, and D. Millan, RNA splicing factors regulated by HPV16 during cervical tumour progression, J Pathol, vol.219, pp.383-391, 2009.

G. M. Hayes, P. E. Carrigan, A. M. Beck, and L. J. Miller, Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma, Cancer Res, vol.66, pp.3819-3827, 2006.

G. M. Hayes, P. E. Carrigan, and L. J. Miller, Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas, Cancer Res, vol.67, pp.2072-2080, 2007.

S. W. Jang, S. J. Yang, A. Ehlen, S. Dong, and H. Khoury, Serine/arginine protein-specific kinase 2 promotes leukemia cell proliferation by phosphorylating acinus and regulating cyclin A1, Cancer Res, vol.68, pp.4559-4570, 2008.

J. F. Caceres, T. Misteli, G. R. Screaton, D. L. Spector, and A. R. Krainer, Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity, J Cell Biol, vol.138, pp.225-238, 1997.

J. W. Neal, Histology matters: individualizing treatment in non-small cell lung cancer, Oncologist, vol.15, pp.3-5, 2010.

P. Wheatley-price, F. Blackhall, S. M. Lee, C. Ma, and L. Ashcroft, The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials, Ann Oncol, vol.21, pp.2023-2028, 2010.

C. J. Langer, B. Besse, A. Gualberto, E. Brambilla, and J. C. Soria, The evolving role of histology in the management of advanced non-small-cell lung cancer, J Clin Oncol, vol.28, pp.5311-5320, 2010.

R. Xiao, Y. Sun, J. H. Ding, S. Lin, and D. W. Rose, Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis, Mol Cell Biol, vol.27, pp.5393-5402, 2007.

C. Ghigna, D. Toledo, M. Bonomi, S. Valacca, C. Gallo et al., Prometastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives, RNA Biol, vol.7, pp.495-503, 2010.
URL : https://hal.archives-ouvertes.fr/hal-02193461